Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 32

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 32
---
 Restated Certificate of Incorporation, our board of directors is authorized to issue up to 5,000,000 shares of our preferred stock, par value $0.00001 per share, in one or more series without stockholder approval. As of September 30, 2022, we had no shares of preferred stock outstanding. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock. The purpose of authorizing our board of directors to issue preferred stock and determine its rights and preferences is to eliminate delays associated with a stockholder vote on specific issuances. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions, future financings and other corporate purposes, could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a majority of our outstanding voting stock. If we offer a specific class or series of preferred stock under this prospectus, we will describe the terms of the preferred stock in the prospectus supplement for such offering and will file a copy of the certificate establishing the terms of the preferred stock with the Commission. To the extent appropriate, this description will include, where applicable:

| • |     | the title and stated value; |

| • |     | the number of shares offered, the liquidation preference per share and the purchase price; |

| • |     | the dividend rate(s), period(s) and/or payment date(s), or method(s) of calculation for such dividends; |

| • |     | whether dividends will be cumulative or non-cumulative and, if 
 cumulative, the date from which dividends will accumulate;     |

| • |     | the procedures for any auction and remarketing, if any; |

| • |     | the provisions for a sinking fund, if any; |

| • |     | the provisions for redemption, if applicable; |

| • |     | any listing of the preferred stock on any securities exchange or market; |

| • |     | whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price 
 (or how it will be calculated) and conversion period;                                                           |

| • |     | voting rights, if any, of the preferred stock; |

| • |     | a discussion of any material U.S. federal income tax considerations applicable to the preferred stock; |

|